Document Detail


Evaluation of new antifungal drugs for the treatment of systemic fungal infections. Infectious Diseases Society of America and the Food and Drug Administration.
MedLine Citation:
PMID:  1477243     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
These guidelines are applicable to all fungal pathogens that produce systemic infections in humans. Specific examples are provided whenever they might clarify special issues. Systemic fungal infections usually are divided into two broad categories: endemic systemic fungal diseases, which occur classically in healthy hosts, and opportunistic fungal diseases, which occur almost exclusively in patients with impaired host defenses. Both the increasing frequency of disseminated histoplasmosis and coccidioidomycosis in patients with AIDS and the occurrence of candidemia due to vascular-line infections have begun to blur this distinction. The fungi included in these guidelines are Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Candida species, Cryptococcus neoformans, Aspergillus species, and Sporothrix schenckii. Diagnosis of infections caused by these fungi should be based on culture of infected body fluids or tissues whenever possible. Cryptococcal and coccidioidal meningitis are exceptions. Amphotericin B remains the standard comparative agent for most new agents. Further studies of the efficacy of new oral agents used alone or after a hospital course of amphotericin B are needed. The agents currently available are usually inadequate for eradication of fungal infections in patients with AIDS, who may need prolonged treatment. Final assessment for these patients may need to be classified as clinical cure with presumed microbiologic persistence.
Authors:
G Medoff; W E Dismukes; D Pappagianis; R Diamond; H A Gallis; D Drutz
Related Documents :
7739653 - Prophylaxis of candida and aspergillus infections with oral administration of itraconaz...
19384753 - Potential contribution of fungal infection and colonization to the development of allergy.
2613853 - Logistic and poisson models for infection by multicomponent plant viruses.
Publication Detail:
Type:  Guideline; Journal Article; Practice Guideline; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America     Volume:  15 Suppl 1     ISSN:  1058-4838     ISO Abbreviation:  Clin. Infect. Dis.     Publication Date:  1992 Nov 
Date Detail:
Created Date:  1993-02-05     Completed Date:  1993-02-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9203213     Medline TA:  Clin Infect Dis     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S274-81     Citation Subset:  IM; X    
Affiliation:
Infectious Diseases Division, Washington University School of Medicine, St. Louis, Missouri 63110.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antifungal Agents / therapeutic use*
Clinical Protocols / standards
Clinical Trials as Topic / standards*
Clinical Trials, Phase I as Topic / standards
Clinical Trials, Phase II as Topic / standards
Clinical Trials, Phase III as Topic / standards
Humans
Mycoses / drug therapy*
Research Design
Grant Support
ID/Acronym/Agency:
HHS 223-88-1301/HS/AHRQ HHS
Chemical
Reg. No./Substance:
0/Antifungal Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation of new anti-infective drugs for the treatment of gastritis and peptic ulcer disease assoc...
Next Document:  Evaluation of new anti-infective drugs for the treatment and prevention of tuberculosis. Infectious ...